NanoViricides at 2024 EF Hutton Global Conference in NYC on May 15

NanoViricides, Inc., a prominent player in the field of antiviral nanomedicines, has announced that its President and Executive Chairman, Dr. Anil R. Diwan, will be participating in the EF Hutton Annual Global Conference at The Plaza Hotel in New York, NY on May 15, 2024. This event will gather executives from various public and private companies, providing them an opportunity to share their progress and strategies with investors, corporate clients, high-net-worth individuals, and members of the press in an engaging environment.

Dr. Diwan is scheduled to present the advancements made by NanoViricides over the past year, particularly focusing on their leading antiviral drug, NV-387. Dr. Diwan highlighted that NV-387 has the potential to revolutionize the treatment of viral infections in a manner akin to the impact of penicillin on bacterial infections.

NV-387 has successfully completed Phase 1a/1b human clinical trials in healthy volunteers, with no adverse events reported, underscoring its excellent safety profile. These trials were sponsored by Karveer Meditech Pvt. Ltd., NanoViricides' licensee and collaborator, and conducted by PristynCR in India. NV-387 has demonstrated significant antiviral activity against various virus families, including Coronaviruses (SARS-CoV-2, Long COVID, and seasonal coronaviral infections), RSV, Influenza A, and a Smallpox/Mpox-related mouse virus in rigorous animal models. In these tests, NV-387's effectiveness in improving survival rates either matched or surpassed that of approved drugs or known antiviral agents.

NV-387 holds promise as a single drug capable of treating the "tripledemic" of viral infections, including Coronaviruses, RSV, and Influenza A. Following the completion of the Phase I final report, NanoViricides plans to advance NV-387 into Phase II clinical trials to further evaluate its antiviral effects. If these trials are successful, the company anticipates moving forward to Phase III clinical trials, aiming for regulatory approval to treat various viral infections.

In addition to NV-387, NanoViricides boasts a diverse pipeline of drug candidates targeting multiple virus families. Among these, NV-HHV-1 is the leading candidate for treating Shingles rash, HSV-1 "cold sores," and HSV-2 "genital ulcers."

EF Hutton, the host of the annual conference, is an investment bank based in New York, NY, known for providing strategic advice and financing solutions to middle-market and emerging growth companies. The bank has a strong track record, having raised over $15.8 billion in capital across more than 265 transactions since 2022. EF Hutton is recognized as a leader in SPAC issuance and US IPO issuance, making it one of the most active investment banks in the middle market sector.

NanoViricides, Inc., established in 2005, focuses on developing special-purpose nanomaterials for antiviral therapy. Their innovative nanoviricide® class of drug candidates is designed to target and dismantle enveloped virus particles. These drugs mimic host-side features that viruses require, making it difficult for viruses to escape the therapeutic effects of nanoviricides. The company holds exclusive licenses for a range of human viral diseases from TheraCour Pharma, Inc., and continues to develop drugs for various viral infections, including HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus.

NanoViricides is dedicated to advancing its drug candidates through clinical trials and aims to secure regulatory approvals. The company acknowledges that drug development is a lengthy and capital-intensive process, with no guarantees of effectiveness and safety in human clinical development. Nonetheless, NanoViricides remains committed to its mission of developing groundbreaking antiviral therapies.